Corvus Pharmaceuticals’ (CRVS) Neutral Rating Reiterated at Mizuho

Corvus Pharmaceuticals (NASDAQ:CRVS)‘s stock had its “neutral” rating reaffirmed by research analysts at Mizuho in a report issued on Wednesday, Benzinga reports. They currently have a $3.50 target price on the stock. Mizuho’s target price indicates a potential upside of 96.63% from the company’s current price.

Separately, Oppenheimer decreased their target price on Corvus Pharmaceuticals from $8.00 to $7.00 and set an “outperform” rating for the company in a research note on Wednesday, March 20th.

Corvus Pharmaceuticals Stock Down 0.6 %

Shares of NASDAQ:CRVS opened at $1.78 on Wednesday. The business has a 50 day moving average price of $2.09 and a 200 day moving average price of $1.75. Corvus Pharmaceuticals has a twelve month low of $0.66 and a twelve month high of $4.19. The company has a market cap of $87.29 million, a price-to-earnings ratio of -3.12 and a beta of 1.04.

Hedge Funds Weigh In On Corvus Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. Marshall Wace LLP acquired a new stake in shares of Corvus Pharmaceuticals during the second quarter worth $685,000. Towerview LLC raised its stake in Corvus Pharmaceuticals by 67.1% in the third quarter. Towerview LLC now owns 342,478 shares of the company’s stock valued at $500,000 after buying an additional 137,478 shares during the period. Two Sigma Advisers LP raised its stake in Corvus Pharmaceuticals by 28.6% in the third quarter. Two Sigma Advisers LP now owns 480,100 shares of the company’s stock valued at $393,000 after buying an additional 106,700 shares during the period. Goldman Sachs Group Inc. acquired a new position in shares of Corvus Pharmaceuticals in the second quarter valued at approximately $216,000. Finally, Two Sigma Investments LP grew its position in shares of Corvus Pharmaceuticals by 19.0% in the third quarter. Two Sigma Investments LP now owns 429,708 shares of the company’s stock valued at $352,000 after purchasing an additional 68,674 shares during the last quarter. Institutional investors own 46.64% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers.